Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2021 - 06 - 11 source : Www.fda.gov save search
FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Published: 2021-06-11 (Crawled : 18:17) - fda.gov
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
fda fda approval cancer
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.5%
H: 0.33%
C: -3.67%
approval fda granted cancer prostate cancer grant
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $133.91 0.89% 0.0% 850K
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.12%
approval fda fda approval nivolumab
Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
Published: 2021-06-11 (Crawled : 17:44) - fda.gov
SUPN | $29.71 1.05% 1.04% 350K
|
Health Technology
|
| O: 0.0%
H: 0.28%
C: -1.98%
drug food
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
Published: 2021-06-11 (Crawled : 17:07) - fda.gov
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -2.79%
H: 1.13%
C: -1.29%
fda approval fda approval
FDA Takes Steps to Increase Availability of COVID-19 Vaccine
Published: 2021-06-11 (Crawled : 15:15) - fda.gov
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.01%
H: 0.01%
C: -1.26%
covid fda vaccine covid-19
FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Published: 2021-06-11 (Crawled : 14:04) - fda.gov
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: 0.0%
H: 0.1%
C: -0.71%
fda granted approval leukemia myeloid leukemia grant acute myeloid leukemia
FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
Published: 2021-06-11 (Crawled : 13:55) - fda.gov
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.5%
H: 0.33%
C: -3.67%
cancer test fda fda approval diagnostic biomarkers
FDA approves selinexor for refractory or relapsed multiple myeloma
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
KPTI | $1.12 -4.27% -4.46% 770K
|
Health Technology
|
| O: 1.61%
H: 0.09%
C: -3.73%
fda approval fda approval
FDA approves pralsetinib for RET-altered thyroid cancers
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
BPMC | $90.69 4.42% 4.23% 780K
|
Health Technology
|
| O: 1.41%
H: 2.24%
C: 1.88%
cancer fda approval fda approval
FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
YMAB | $15.2 0.46% 0.46% 470K
|
Health Technology
|
| O: 0.05%
H: 1.54%
C: -3.36%
risk fda granted approval grant
FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression
Published: 2021-06-11 (Crawled : 13:10) - fda.gov
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: -0.52%
H: 0.18%
C: -0.7%
cancer fda fda approval
FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Published: 2021-06-11 (Crawled : 13:02) - fda.gov
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -0.14%
H: 0.42%
C: 0.14%
fda fda approval cell carcinoma
FDA approves isatuximab-irfc for multiple myeloma
Published: 2021-06-11 (Crawled : 12:53) - fda.gov
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
fda approval fda approval
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
Published: 2021-06-11 (Crawled : 12:43) - fda.gov
ADCT | $4.69 -0.64% 0.0% 170K
|
Health Technology
|
| O: -0.18%
H: 2.19%
C: 0.14%
fda granted approval grant t-cell
FDA approves nivolumab for resected esophageal or GEJ cancer
Published: 2021-06-11 (Crawled : 12:24) - fda.gov
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.74%
H: 0.07%
C: -0.81%
cancer fda approval fda approval nivolumab
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.